ACM
ADMA icon

Aubrey Capital Management’s ADMA Biologics ADMA Stock Holding History

Aubrey Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-189,800
Closed -$3.45M – 53
2025
Q2 		$3.45M Buy
+189,800
New +$3.87M 1.25% 28

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.15B AUM 48.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Aubrey Capital Management's ADMA Position: Q3 2025 in Review

Aubrey Capital Management sold out of ADMA Biologics (ADMA) in Q3 2025, closing a stake of 189,800 shares — an estimated $3.45M sold.

Aubrey Capital Management first reported a position in ADMA in Q2 2025 and held it in 1 quarter. The position peaked at $3.45M in Q2 2025. 365 funds tracked by Wall St. Rank hold ADMA as of Q3 2025.

  • Aubrey Capital Management reported no remaining ADMA Biologics position as of Q3 2025 after selling out during the quarter.
  • Aubrey Capital Management sold 189,800 ADMA Biologics shares in Q3 2025, an estimated $3.45M.
  • Aubrey Capital Management first reported a position in ADMA Biologics in Q2 2025 and held it in 1 quarter.
  • Aubrey Capital Management's ADMA Biologics position peaked at $3.45M in Q2 2025.
  • 365 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2025.

Based on Aubrey Capital Management's 13F filing for Q3 2025, filed 30 Oct 2025.